Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma

Biochemical and Biophysical Research Communications

Volumn 420, Issue 3, 2012, Pages 644-650

  Gu, Jing Li ^a   Li, Juan ^a   Zhou, Zheng Hai ^a   Liu, Jun Ru ^a   Huang, Bei Hui ^a   Zheng, Dong ^a   Su, Chang ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Bortezomib; Differentiation; Drug resistance; Multiple myeloma

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN LIGHT CHAIN; PROTEASOME; RETINOIC ACID; X BOX BINDING PROTEIN 1;

APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL STRUCTURE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; FEASIBILITY STUDY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOGLOBULIN PRODUCTION; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SECRETION; STRUCTURE ANALYSIS;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL DIFFERENTIATION; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; HUMANS; MULTIPLE MYELOMA; PYRAZINES; TRANSCRIPTION FACTORS; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 84859625301     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.03.056     Document Type: Article

References (30)

1. Kyle R.A., Rajkumar S.V. Multiple myeloma. N. Engl. J. Med. 2004, 351:1860-1873.
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J. Clin. 2007, 57(2007):43-66.
3. Boccadoro M., Morgan G., Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int. 2005, 5:18.
4. Rumpold H., Salvador C., Wolf A.M., et al. Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors. Biochem. Biophys. Res. Commun. 2007, 361:549-554.
5. Wu X., Shao Y., Tao Y., et al. Proteasome inhibitor lactacystin augments natural killer cell cytotoxicity of myeloma via downregulation of HLA class I. Biochem. Biophys. Res. Commun. 2011, 415:187-192.
6. Bianchi G., Oliva L., Cascio P., et al. The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood 2009, 113:3040-3049.
7. Meister S., Schubert U., Neubert K., et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 2007, 67:1783-1792.
8. Schubert U., Anton L.C., Gibbs J., et al. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 2000, 404:770-774.
9. Goldberg A.L. Protein degradation and protection against misfolded or damaged proteins. Nature 2003, 426:895-899.
10. Wuilleme-Toumi S., Trichet V., Gomez-Bougie P., et al. Reciprocal protection of Mcl-1 and Bim from ubiquitin-proteasome degradation. Biochem. Biophys. Res. Commun. 2007, 361:865-869.
11. Zhou Y., Goodenbour J.M., Godley L.A., et al. High levels of tRNA abundance and alteration of tRNA charging by bortezomib in multiple myeloma. Biochem. Biophys. Res. Commun. 2009, 385:160-164.
12. Hou J., Xiong H., Gao W., et al. 2-Methoxyestradiol at low dose induces differentiation of myeloma cells. Leuk. Res. 2005, 29:1059-1067.
13. Huang H., Wu D., Fu J., et al. All-trans retinoic acid can intensify the growth inhibition and differentiation induction effect of rosiglitazone on multiple myeloma cells. Eur. J. Haematol. 2009, 83:191-202.
14. Turilova V.I., Smirnova T.D., Samoilovich M.P., et al. Functional morphology of nucleolus organizer regions of chromosomes and nucleoli in human multiple myeloma cell lines. I. Variation of the morphology and silver staining of nucleolus organizer regions of chromosomes in RMPI 8226 and U 266 cell lines with different level of differentiation of during 7days after cell passage]. Tsitologiia 1998, 40:536-548.
15. Salmon S.E. Immunoglobulin synthesis and tumor kinetics of multiple myeloma. Semin. Hematol. 1973, 10:135-144.
16. Reimold A.M., Iwakoshi N.N., Manis J., et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature 2001, 412:300-307.
17. Nakamura M., Gotoh T., Okuno Y., et al. Activation of the endoplasmic reticulum stress pathway is associated with survival of myeloma cells. Leuk. Lymphoma 2006, 47:531-539.
18. Grignani F., Fagioli M., Alcalay M., et al. Acute promyelocytic leukemia: from genetics to treatment. Blood 1994, 83:10-25.
19. Greipp P.R., Raymond N.M., Kyle R.A., et al. Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood 1985, 65:305-310.
20. Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 2005, 352:2487-2498.
21. Cenci S., Mezghrani A., Cascio P., et al. Progressively impaired proteasomal capacity during terminal plasma cell differentiation. EMBO J. 2006, 25:1104-1113.
22. Cascio P., Oliva L., Cerruti F., et al. Dampening Ab responses using proteasome inhibitors following in vivo B cell activation. Eur. J. Immunol. 2008, 38:658-667.
23. Neubert K., Meister S., Moser K., et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat. Med. 2008, 14:748-755.
24. Huang L., Chen C.H. Proteasome regulators: activators and inhibitors. Curr. Med. Chem. 2009, 16:931-939.
25. Liu Y., Liu X., Zhang T., et al. Cytoprotective effects of proteasome beta5 subunit overexpression in lens epithelial cells. Mol. Vis. 2007, 13:31-38.
26. Kwak M.K., Huang B., Chang H., et al. Tissue specific increase of the catalytic subunits of the 26S proteasome by indirect antioxidant dithiolethione in mice: enhanced activity for degradation of abnormal protein. Life Sci. 2007, 80:2411-2420.
27. Du Z.X., Meng X., Zhang H.Y., et al. Caspase-dependent cleavage of BAG3 in proteasome inhibitors-induced apoptosis in thyroid cancer cells. Biochem. Biophys. Res. Commun. 2008, 369:894-898.
28. Magill L., Lynas J., Morris T.C., et al. Proteasome proteolytic activity in hematopoietic cells from patients with chronic myeloid leukemia and multiple myeloma. Haematologica 2004, 89:1428-1433.
29. Aghajanian C., Soignet S., Dizon D.S., et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. 2002, 8:2505-2511.
30. Cortes J., Thomas D., Koller C., et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin. Cancer Res. 2004, 10:3371-3376.